BSc (Hons) in Biochemistry from University of Cape Town. Working in regulatory affairs and clinical development for over 30 years with focus on biological medicines and particular expertise in biosimilars. Joined PAREXEL in 2001 prior to which was with Novo Nordisk Ltd.

Seasoned life sciences executive and strategy consulting leader experienced in asset and franchise growth strategy and mergers and acquisitions/transactions advisory support. Skilled in leading domestic and global teams in marketing strategy, portfolio management, new product commercialization, and market access. Functional expertise in strategy development, life cycle management, valuation, diligence, and digital health. Therapeutic and technical focus in autoimmune and CNS diseases and drug delivery devices and formulation technologies. Have advised or supported integration of >$40B in life sciences transactions.